Efficacy and safety of abatacept for systemic juvenile idiopathic arthritis: a systematic review.

Kenichi Nishimura Takashi IshikawaNami OkamotoKeiji AkamineNatsumi InoueHitoshi IrabuKentaro KatoHiroshi KeinoMasayo KojimaHiroshi KuboKazuichi MaruyamaMao MizutaKosuke ShabanaMasaki ShimizuYuko SugitaYukiko TakakuwaSatoshi TakanashiHiroshi TakaseHiroaki UmebayashiNatsuka UmezawaShingo YamanishiKazuko YamazakiMasato YashiroTakahiro YasumiMasaaki Mori

Published in: Modern rheumatology (2024)

Abatacept improved the disease activity index. In addition, abatacept was as safe as interleukin-6 (IL -6) and IL-1 inhibitors. However, both the efficacy and safety data in this systematic review should be reviewed with caution because their quality of evidence is low or very low. Further studies are needed to confirm the efficacy and safety of abatacept for systemic JIA, especially its efficacy on joint symptoms.

Keyphrases

disease activity
juvenile idiopathic arthritis
rheumatoid arthritis
rheumatoid arthritis patients
systematic review
ankylosing spondylitis
systemic lupus erythematosus
electronic health record
big data
case control
machine learning
quality improvement
data analysis